Strengthening Domestic Drug Production and Supply Chain Security
This act aims to enhance drug supply security in the United States by supporting domestic production of critical ingredients. Citizens can expect greater drug availability and reduced risk of shortages, contributing to healthcare stability. Pharmaceutical companies will be required to disclose more information about their supply chains, increasing transparency.
Key points
Creation of a confidential list of drugs critical for public health and national security, updated every two years.
Boosting domestic manufacturing of drug ingredients through contracts with US-based companies, requiring 3-month supply reserves.
Prioritized procurement of US-manufactured drugs by federal agencies like the Department of Defense and Veterans Affairs.
Increased transparency in drug supply chains, including reporting on foreign ingredient sources and contingency plans.
Oversight of foreign investment in the US pharmaceutical industry to protect domestic production capabilities.
Expired
Citizen Poll